A general framework for assessing IVIVC as a tool for maximizing the benefit-risk ratio of a treatment using a convolution-based modeling approach.

Related Articles

A general framework for assessing IVIVC as a tool for maximizing the benefit-risk ratio of a treatment using a convolution-based modeling approach.

CPT Pharmacometrics Syst Pharmacol. 2019 Jan 18;:

Authors: Gomeni R, Fang LL, Bressolle-Gomeni F, Spencer TJ, Faraone SV, Babiskin A

Abstract
The net benefit of a treatment can be defined by the relationship between clinical improvement and risk of adverse events: the benefit-risk ratio. The optimization of the benefit-risk ratio can be achieved by identifying the most adequate dose (and/or dosage regimen) jointly with the best performing in-vivo release properties of a drug. A general in-silico tool is presented for identifying the dose, the in-vitro and the in-vivo release properties that maximize the benefit-risk ratio using convolution-based modeling, an exposure-response model, and a surface response analysis. A case study is presented to illustrate how the benefit-risk ratio of methylphenidate for the treatment of Attention-Deficit/Hyperactivity Disorder can be maximized using the proposed strategy. The results of the analysis identified the characteristics of an optimized dose and in-vitro/in-vivo release suitable to provide a sustained clinical response with respect to the conventional dosage regimen and formulations. This article is protected by copyright. All rights reserved.

PMID: 30659771 [PubMed – as supplied by publisher]

via https://www.ncbi.nlm.nih.gov/pubmed/30659771?dopt=Abstract